We use necessary cookies to make our site work. We'd also like to set optional analytics cookies to help us improve it. We won't set optional cookies unless you enable them.
We utilise Google Analytics cookies to help us to improve our website by collecting information on how it's used.
Find out more
Radiotherapy is the most cost-effective cancer treatment strategy applied to more than 60% of cancer patients and is responsible for over 50% of cancer cures. Technological improvements in the last couple of decades have allowed delivery of doses with much greater conformality to the tumour volumes. However, damage to the surrounding healthy tissue is unavoidable and remains one of the major limiting factors in how much radiation dose can be prescribed to a patient.
Current radiotherapy practice aims to maximise the radiation dose delivered to the tumour volume whilst minimising that absorbed by the healthy tissues. However, absorbed dose is only a surrogate for the response of cells and tissues exposed to ionizing radiation and radiation effects are the result of complex interplay between physical, chemical and biological processes. There is therefore an increasing drive to take into consideration not just the physical dose but also the biologically intrinsic characteristics of patients and tumours, to provide additional parameters with which to optimise treatments. Improved knowledge of the response of both normal and cancer cells/tissues to radiation is significant in the move towards more personalised radiotherapy treatments.
NPL is supporting the development and clinical implementation of biologically optimised radiotherapy through the following activities:
Find out more about NPL's Radiotherapy and diagnostic services
Find out more about Pre-clinical dosimetry studies at NPL
Our research and measurement solutions support innovation and product development. We work with companies to deliver business advantage and commercial success. Contact our Customer Services team on +44 20 8943 7070